Literature DB >> 9316125

Accuracy of cytogenetic findings on chorionic villus sampling (CVS)--diagnostic consequences of CVS mosaicism and non-mosaic discrepancy in centres contributing to EUCROMIC 1986-1992.

J M Hahnemann1, L O Vejerslev.   

Abstract

Of 62,865 karyotyped chorionic villus (CV) samples that were reported to EUCROMIC 1986-1992, 98.5 per cent showed either a normal karyotype (true negative result; 94.8 per cent of the total) or a non-mosaic chromosomal aberration (true positive non-mosaic result; 3.7 per cent). True fetal mosaicism was diagnosed in about 0.15 per cent of the 62,865 CV samples, while confined placental mosaicism (CPM) occurred in 1.0 per cent. False-positive non-mosaic aberrations were observed in 0.15 per cent and false-negative CVS (chorionic villus sampling) results in only 0.03 per cent. The remaining 0.15 per cent of the CVS results were unclassifiable. These figures determined a sensitivity of CVS for prenatal detection of chromosome aberrations of 98.9-99.6 per cent (95 per cent confidence intervals), a specificity of 98.5-98.8 per cent, a positive predictive value of 72.6-78.3 per cent, and a negative predictive value of 99.95-99.98 per cent. False-positive non-mosaic aberrations that could not from the outset be suspected of being confined to the placenta were very rare (0.07 per cent of CV samples). They most often involved non-mosaic monosomy X and trisomy 18 encountered after direct preparation alone. False-negative CVS results were extremely rare (0.03 per cent) and occurred, with only one exception, after direct preparation alone. Thirteen of the 19 false-negative CVS diagnoses were from pregnancies at a particularly high risk for fetal chromosomal aberration. Seventy-five per cent of the pregnancies with CVS mosaicism or non-mosaic discrepancy and known outcome continued to livebirth. When CVS mosaicism was encountered, the definitive prenatal cytogenetic diagnosis was most often obtained through subsequent amniocentesis. However, the use of amniocentesis and the frequency of pregnancy termination depended on the type of chromosomal aberration involved. We conclude that CVS is an accurate method for prenatal chromosome analysis. In pregnancies at high risk for fetal chromosomal abnormality, we recommend, however, not relying solely on a normal karyotype obtained after direct preparation alone.

Mesh:

Year:  1997        PMID: 9316125     DOI: 10.1002/(sici)1097-0223(199709)17:9<801::aid-pd153>3.0.co;2-e

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  19 in total

1.  Detection of chromosome aneuploidies in chorionic villus samples by multiplex ligation-dependent probe amplification.

Authors:  Angelique J A Kooper; Brigitte H W Faas; Ton Feuth; Johan W T Creemers; Hans H Zondervan; Peter F Boekkooi; Rik W P Quartero; Robbert J P Rijnders; Ineke van der Burgt; Ad Geurts van Kessel; Arie P T Smits
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

2.  Noninvasive prenatal testing using a novel analysis pipeline to screen for all autosomal fetal aneuploidies improves pregnancy management.

Authors:  Baran Bayindir; Luc Dehaspe; Nathalie Brison; Paul Brady; Simon Ardui; Molka Kammoun; Lars Van der Veken; Klaske Lichtenbelt; Kris Van den Bogaert; Jeroen Van Houdt; Hilde Peeters; Hilde Van Esch; Thomy de Ravel; Eric Legius; Koen Devriendt; Joris R Vermeesch
Journal:  Eur J Hum Genet       Date:  2015-01-14       Impact factor: 4.246

3.  The importance of screening and prenatal diagnosis in the identification of the numerical chromosomal abnormalities.

Authors:  Daniela Neagos; Ruxandra Cretu; Roxana Corina Sfetea; Laurentiu Camil Bohiltea
Journal:  Maedica (Bucur)       Date:  2011-07

Review 4.  Review: cell-free fetal DNA in the maternal circulation as an indication of placental health and disease.

Authors:  E S Taglauer; L Wilkins-Haug; D W Bianchi
Journal:  Placenta       Date:  2013-12-01       Impact factor: 3.481

Review 5.  Integration of noninvasive DNA testing for aneuploidy into prenatal care: what has happened since the rubber met the road?

Authors:  Diana W Bianchi; Louise Wilkins-Haug
Journal:  Clin Chem       Date:  2013-11-19       Impact factor: 8.327

Review 6.  Noninvasive prenatal testing: the future is now.

Authors:  Errol R Norwitz; Brynn Levy
Journal:  Rev Obstet Gynecol       Date:  2013

7.  Noninvasive prenatal aneuploidy testing of chromosomes 13, 18, 21, X, and Y, using targeted sequencing of polymorphic loci.

Authors:  Bernhard Zimmermann; Matthew Hill; George Gemelos; Zachary Demko; Milena Banjevic; Johan Baner; Allison Ryan; Styrmir Sigurjonsson; Nikhil Chopra; Michael Dodd; Brynn Levy; Matthew Rabinowitz
Journal:  Prenat Diagn       Date:  2012-10-30       Impact factor: 3.050

Review 8.  Noninvasive fetal genome sequencing: a primer.

Authors:  Matthew W Snyder; LaVone E Simmons; Jacob O Kitzman; Donna A Santillan; Mark K Santillan; Hilary S Gammill; Jay Shendure
Journal:  Prenat Diagn       Date:  2013-04-01       Impact factor: 3.050

9.  Biological explanations for discordant noninvasive prenatal test results: Preliminary data and lessons learned.

Authors:  Louise Wilkins-Haug; Chengsheng Zhang; Eliza Cerveira; Mallory Ryan; Adam Mil-Homens; Qihui Zhu; Honey Reddi; Charles Lee; Diana W Bianchi
Journal:  Prenat Diagn       Date:  2018-05       Impact factor: 3.050

10.  Fetoplacental discrepancy with normal karyotype in amniotic fluid and two different cell lines in placenta.

Authors:  Veronica Ortega; Christina Mendiola; Eric Williamson; Kenneth Higby; Gopalrao V N Velagaleti
Journal:  Case Rep Genet       Date:  2013-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.